Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 8Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Smoldering Multiple Myeloma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms by Histologic Type 1Neoplasms 1Multi-centric Castleman's Disease 1Monoclonal Gammopathy of Undetermined Significance 1Macular dystrophy, corneal type 1 1Lymphoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Cytokine Release Syndrome 1Colorectal Neoplasms 1Castleman Disease 1Carcinoma, Renal Cell 1

Interventions

tocilizumab 1tanespimycin 1siltuximab 1Zidovudine 1Valganciclovir 1Polymerase Chain Reaction 1Histological Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Multi-centric Castleman's Disease × siltuximab × Clear all
NCT01024036 2018-03-21

A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

Janssen Research & Development, LLC

Phase 2 Completed
79 enrolled 20 charts

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡